DalsnaFinance Account

Kenvue $KVUE

Consumer Staples · Personal Care Products · NYSE/NASDAQ

S&P 500 Russell 1000 New Jersey

Create a scorecard

$19.15

+0.28 (+1.49%)

As of Oct 20, 2026, 12:08 PM EDT · cached

Price history

Loading chart…

Key facts

52-week range (closes): $14.11 – $19.83 Lowest close Oct 16, 2025, highest Jul 2, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings: Nov 2, 2026 · EPS forecast $0.28 Nasdaq earnings calendar, as of Oct 20, 2026
Fiscal year ends: December Fiscal 2025 ended Dec 28, 2025, from SEC filings
In the S&P 500 since: Aug 25, 2023, replacing Advance Auto Parts (AAP) · Johnson & Johnson offered to exchange the shares of Kenvue held for shares of Johnson & Johnson in a split-off exchange offer. · All S&P 500 changes
IPO: May 4, 2023 · priced at $22.00 · NYSE · IPO details

Kenvue (KVUE) is trading up at $19.15 (+1.49%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Consumer Staples sector.

Kenvue revenue & net income history (FY2021–FY2025)

RevenueNet incomeNet margin (right axis, %)

Kenvue annual financial statements
	FY2021Jan 2022	FY2022Jan 2023	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$15.1B	$14.9B	$15.4B	$15.5B	$15.1B
Growth (year over year)	—	−0.7%	+3.3%	+0.1%	−2.1%
Gross profit	$8.42B	$8.29B	$8.64B	$8.96B	$8.79B
Gross margin	55.9%	55.4%	56.0%	58.0%	58.1%
Operating income	$2.92B	$2.67B	$2.51B	$1.84B	$2.41B
Operating margin	19.4%	17.9%	16.3%	11.9%	16.0%
Net income	$2.08B	$2.06B	$1.66B	$1.03B	$1.47B
Net margin	13.8%	13.8%	10.8%	6.7%	9.7%
EPS (diluted)	$1.21	$1.20	$0.90	$0.54	$0.76
Balance sheet
Cash and equivalents	$740.0M	$1.23B	$1.38B	$1.07B	$1.06B
Total assets	—	$27.3B	$27.9B	$25.6B	$27.1B
Total liabilities	—	$7.35B	$16.6B	$15.9B	$16.3B
Long-term debt	—	$0	$7.69B	—	—
Shareholders' equity	$20.5B	$20.0B	$11.2B	$9.67B	$10.8B
Cash flow
Operating cash flow	$334.0M	$2.52B	$3.17B	$1.77B	$2.20B
Capital expenditure	$295.0M	$375.0M	$469.0M	$434.0M	$475.0M
Free cash flow	$39.0M	$2.15B	$2.70B	$1.33B	$1.72B
Dividends paid	$0	$0	$766.0M	$1.55B	$1.58B
Share buybacks	—	$0	$7.00M	$235.0M	$197.0M

RevenueNet incomeNet margin (right axis, %)

Kenvue quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$3.90B	$3.66B	$3.74B	$3.84B	$3.76B	$3.78B	$3.91B	$3.96B
Growth (year over year)	−0.4%	−0.1%	−3.9%	−4.0%	−3.5%	+3.2%	+4.5%	+3.0%
Gross profit	$2.28B	$2.07B	$2.17B	$2.26B	$2.23B	$2.14B	$2.30B	$2.30B
Gross margin	58.5%	56.5%	58.0%	58.9%	59.1%	56.5%	58.9%	58.2%
Operating income	$654.0M	$483.0M	$558.0M	$692.0M	$629.0M	$535.0M	$767.0M	$699.0M
Operating margin	16.8%	13.2%	14.9%	18.0%	16.7%	14.2%	19.6%	17.7%
Net income	$383.0M	$293.0M	$322.0M	$420.0M	$398.0M	$330.0M	$474.0M	$456.0M
Net margin	9.8%	8.0%	8.6%	10.9%	10.6%	8.7%	12.1%	11.5%
EPS (diluted)	$0.20	$0.16	$0.17	$0.22	$0.21	$0.16	$0.25	$0.24
Balance sheet
Cash and equivalents	$1.06B	$1.07B	$1.06B	$1.07B	$1.14B	$1.06B	$1.07B	$1.11B
Total assets	$26.9B	$25.6B	$26.3B	$27.1B	$27.2B	$27.1B	$26.9B	$26.7B
Total liabilities	$16.3B	$15.9B	$16.2B	$16.4B	$16.6B	$16.3B	$16.2B	$16.2B
Shareholders' equity	$10.6B	$9.67B	$10.1B	$10.7B	$10.6B	$10.8B	$10.6B	$10.6B
Cash flow
Operating cash flow	$249.0M	$793.0M	$428.0M	$621.0M	$294.0M	$854.0M	$489.0M	$688.0M
Capital expenditure	$59.0M	$132.0M	$179.0M	$88.0M	$98.0M	$110.0M	$139.0M	$64.0M
Free cash flow	$190.0M	$661.0M	$249.0M	$533.0M	$196.0M	$744.0M	$350.0M	$624.0M
Dividends paid	$393.0M	$393.0M	$392.0M	$393.0M	$398.0M	$398.0M	$398.0M	$398.0M
Share buybacks	$23.0M	$121.0M	$63.0M	$64.0M	$70.0M	$0	$0	$0

From Kenvue's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Kenvue vs the Consumer Staples sector and the S&P 500

Kenvue's latest reported figures next to the median of the other 33 S&P 500 Consumer Staples companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Kenvue compared with the median Consumer Staples company and the median S&P 500 company
Measure	Kenvue	Consumer Staples (33 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	−2.1%	+2.3%	+7.0%
Net margin, latest fiscal year	9.7%	6.4%	13.0%
Dividend per share, latest fiscal year	$0.82	$2.08	$2.40
Share price change, 1 year	+26.1%	+4.9%	+5.6%

Kenvue: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Kenvue included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 31/496, net margin 31/496, dividend per share 25/349, 1-year price change 32/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 25 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Kenvue

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.

Source: Wikipedia — Kenvue